Aventis Expects Existing Drugs To Fuel Growth

Article Abstract:

Strasbourg, France-based Aventis S.A., which was fomed in 1999 through the merger of Hoechst AG and Rhone Poulenc SA, has reported a loss of $147 million in Euro dollars for 2000. Aventis expects to increase its earnings through sales of key drugs, such as the Allegra allergy medication.

AVE, Allegra (Medication)

---

Aventis's core-business profit jumped 31% in third quarter

Article Abstract:

Aventis S.A. announced net income at its core life-sciences division increased 31% in the third quarter, not including one-time restructuring charges, and revised its full-year growth forecast for net income from 30% to 40%.

---

Aventis will fund U.S. repurchase of modified corn

Article Abstract:

Aventis S.A. will finance a U.S. multimillion-dollar repurchase of StarLink, the company's genetically modified corn.

United States, Corn, Corn Farming, Use of Funds, Corn industry

Similar abstracts:

• Abstracts: Akzo's net falls 7% but beats estimates. Akzo Nobel posts a 30% profit rise for first-quarter. Akzo likely to post a modest increase in 1999 net profit
• Abstracts: Goldman Sachs's net income jumps 31%. Goldman's profit jumps by half on trading success
• Abstracts: Paris signals softening on Aerospatiale. A virtual conquest of Europe. Carrefour catches on to the Internet
• Abstracts: Mmmuffins seeking upscale diners. McDonald's serves it up to Cossette. Veering off from the mainstream
• Abstracts: A fixed interval due-date scheduling problem with earliness and due-date costs. Commonality in product design: cost saving, valuation change and cannibalization

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.